A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results

José Ramón López-Mínguez; Juan Manuel Nogales‐Asensio; Luis Javier Doncel Vecino; Jorge Sandoval; Sebastián Romany; Pedro Martínez Romero; José Díaz; Javier Fernández‐Portales; Reyes González-Fernández; Ginés Martínez Cáceres; Antonio Merchán Herrera; Fernando Alfonso Manterola

doi:10.4244/eijv10i1a10

May 1, 2014EuroIntervention

A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results

View at Publisher

Ask AI

Bookmark

Share

Why the study?

Does paclitaxel-coated balloon pretreatment with BMS improve clinical and angiographic outcomes compared to everolimus DES in patients with bifurcated coronary lesions?

Key Points

To evaluate the 24-month clinical and angiographic outcomes of bifurcation lesion pretreatment with a paclitaxel-eluting balloon plus bare-metal stenting versus everolimus-eluting stenting.
Prospective randomized trial (BABILON trial) evaluating interventions in patients with bifurcated coronary lesions.
Compared paclitaxel-eluting balloon (pDEB) pretreatment with bare-metal stent (BMS) implantation in the main branch against an everolimus drug-eluting stent (DES).
Assessed angiographic late lumen loss and major adverse cardiac events over a 24-month follow-up period.
Main branch pretreatment with a paclitaxel-eluting balloon and bare-metal stent showed greater late lumen loss, though this was not statistically significant (ns), compared to everolimus drug-eluting stents.
Paclitaxel-eluting balloon pretreatment with bare-metal stenting resulted in an increased incidence of major adverse cardiac events compared to everolimus drug-eluting stents.
Both treatment strategies demonstrated similar angiographic and clinical results in the side branch.

Structured PICO

Does paclitaxel-coated balloon pretreatment with BMS improve clinical and angiographic outcomes compared to everolimus DES in patients with bifurcated coronary lesions?

P

Population

Patients with bifurcated coronary lesions

I

Intervention

Paclitaxel-coated balloon (pDEB) bifurcation pretreatment with bare-metal stent (BMS) implantation in the main branch (MB)

C

Comparator

Everolimus drug-eluting stent (DES)

O

Outcome

Late lumen loss (LLL) and major adverse cardiovascular events (MACE)composite

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

In bifurcated coronary lesions, pretreatment with a paclitaxel-coated balloon followed by bare-metal stenting in the main branch resulted in higher MACE rates compared to everolimus drug-eluting stents at 24 months.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

López-Mínguez et al. (2014) studied this question.

synapsesocial.com/papers/69db1797498b35d3e6a3c373 https://doi.org/10.4244/eijv10i1a10

View at Publisher

Ask AI

Bookmark

Share

A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading